Diagnostic Center | April 16, 2024
Novartis reports data from trial of IgA nephropathy treatment
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Subscribe To Our Newsletter & Stay Updated
